Status:
COMPLETED
Efficacy of Pentoxifylline on Chronic Kidney Disease
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Chronic Kidney Disease
Eligibility:
All Genders
20-70 years
Phase:
PHASE4
Brief Summary
To study whether pentoxifylline has additive renoprotective effect in patients taking ARB
Detailed Description
In patients with CKD and serum creatinine 1.3\~6.0 md/gl, having taken losartan 100 mg/day for at least 3 months, with stable renal function, will be recruited to a randomized open-label trial. Patien...
Eligibility Criteria
Inclusion
- Chronic kidney disease with serum creatinine 1.3\~6.0 mg/dl
Exclusion
- History of allergy to pentoxifylline
- Females are nursing or pregnant
- Obstructive uropathy
- Unable to stop chronic immunosuppressive therapy, NSAID
- Congestive heart failure (New York Heart Association functional class III or IV)
- Unstable angina, myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary intervention, within the past 6 months prior to signing the informed consent form
- Cerebral hemorrhage within the past 6 months prior to signing the informed consent form
- Retinal hemorrhage within the past 6 months prior to signing the informed consent form
- Known or suspected secondary hypertension (e.g., primary aldosteronism, renovascular hypertension, pheochromocytoma)
- Severe uncontrolled hypertension with SBP \> 220 mmHg and/or DBP \> 115 mmHg
- Hepatic dysfunction as defined by the following laboratory parameters: ALT or AST \> 2 times the upper limit of the normal range
- Biliary obstructive disorders (e.g. cholestasis)
- Active malignancy
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2007
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00155246
Start Date
July 1 2004
End Date
January 1 2007
Last Update
January 29 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan, 100